SCHEMBL1065906

SCHEMBL1065906

CCC(NC)C(=O)C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.31
TSHR P16473 1/20 0.31
FFAR3 O14843 1/20 0.30
ANPEP P15144 1/20 0.30
ENPEP Q07075 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30595606 0.84 KDM4E (0.32)
SCHEMBL432448 0.79
SCHEMBL805219 0.79
SCHEMBL12155774 0.79
SCHEMBL29790830 0.79 ALDH1A1 (0.42)
SCHEMBL9343006 0.77 SMN1; SMN2 (0.38)
SCHEMBL8829580 0.77
SCHEMBL28263469 0.77
Rubidium SCHEMBL9635582 0.77
Hydrochloric Acid SCHEMBL3290648 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115227819-B Self-oxygen-generating nano-particle for mediating photodynamic inhibition of skin photoaging and preparation method and application thereof 徐州医科大学附属医院 2023-08-29 CN claimed
CN-119630394-A Chelating agents for cancer treatment 普雷高治疗有限公司 2025-03-14 CN disclosed
CN-115068468-B Carboxylic aromatic amides as bradykinin B1 receptor antagonists 拜耳制药股份公司 2025-02-25 CN disclosed
CN-115557907-B 2,4, 5-Trisubstituted 1,2, 4-triazolones as DHODH inhibitors 拜耳股份有限公司 2024-12-06 CN disclosed
CN-113260382-B Cell inhibitory conjugates containing integrin ligands 拜耳医药股份有限公司 2024-09-13 CN disclosed
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
CN-118556062-A Compounds, pharmaceutical compositions and methods for treating, preventing or managing hyperproliferative disorders 文赛克斯制药有限责任公司 2024-08-27 CN disclosed
CN-115137726-B Carboxylic aromatic amides as bradykinin B1 receptor antagonists 拜耳制药股份公司 2024-08-13 CN disclosed
CN-118354796-A Compounds, pharmaceutical compositions and methods for treating, preventing or managing hyperproliferative disorders 文赛克斯制药有限责任公司 2024-07-16 CN disclosed
CN-113348165-B 1,2, 4-Triazin-3 (2H) -one compounds for the treatment of hyperproliferative diseases 拜耳股份有限公司 2024-06-25 CN disclosed
US-20180104185-A1 LIQUID COMPOSITIONS CAPABLE OF FOAMING AND INCLUDING ACTIVE AGENTS, AND METHODS FOR MAKING OR DEVELOPING SAME MIKA PHARMA GMBH 2018-04-19 US disclosed
US-9693956-B2 Liquid compositions capable of foaming and including active agents, and methods for making or developing same MIKA PHARMA GMBH 2017-07-04 US disclosed
EP-2387391-B1 METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY MIKA PHARMA GES FÜR DIE ENTW UND VERMARKTUNG PHARMAZEUTISCHER PRODUKTE MBH (DE) 2017-01-11 EP disclosed
US-20160022579-A1 Liquid Compositions Capable of Foaming and Including Active Agents, and Methods for Making or Developing Same MIKA PHARMA GMBH 2016-01-28 US disclosed
US-9005626-B2 Liquid compositions capable of foaming and including active agents, and methods for making or developing same MIKA PHARMA GMBH (DE) 2015-04-14 US disclosed
EP-2387391-A2 METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY MIKA Pharma Gesellschaft für die Entwicklung und Vermarktung pharmazeutischer Produkte mbH (DE) 2011-11-23 EP disclosed
US-20110269704-A1 METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY MIKA PHARMA GESELLSCHAFT FUR DIE ENTWICKLUNG UND VERMARKTUNG PHARMAZEUTISCHER PRODUKTE MBH (DE) 2011-11-03 US disclosed
WO-2011009436-A9 METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY MIKA PHARMA GESELLSCHAFT FÜR DIE ENTWICKLUNG UND VERMARKTUNG PHARMAZEUTISCHER PRODUKTE MBH (DE) 2011-03-31 WO disclosed
US-20110059117-A1 Liquid Compositions Capable of Foaming and Including Active Agents, and Methods for Making or Developing Same MIKA PHARMA GMBH (DE) 2011-03-10 US disclosed
WO-2011009436-A2 METHOD FOR DEVELOPING A LIQUID COMPOSITION TO BE APPLIED TO THE SKIN AS A FOAM AND A COMPOSITION THAT CAN BE APPLIED TOPICALLY MIKA PHARMA GESELLSCHAFT FÜR DIE ENTWICKLUNG UND VERMARKTUNG PHARMAZEUTISCHER PRODUKTE MBH (DE) 2011-01-27 WO disclosed